NAP1L1 and central nervous system cancer: The upregulation of NAP1L1 increased its binding with c-Myc and, further, activated c-Myc, which induced the expression of CCND1/CDK4 and thereby promoted the resistance to temozolomide and proliferation of glioma cells.